Seeking Alpha

QualityStocks'  Instablog

QualityStocks
Send Message
QualityStocks (www.qualitystocks.net) assists publicly traded companies by getting their story out to the investment community while helping investors discover emerging companies with plenty of growth potential. Our name, QualityStocks, emphasizes our commitment to connect subscribers with... More
My company:
QualityStocks
My blog:
QualityStocks Micro-Cap and Small-Cap Blog
  • New Drug from Sunshine Biopharma, Inc. (SBFM) to Play Critical Role in Fight against Cancer 1 comment
    Oct 21, 2011 2:27 PM | about stocks: SBFM
    It’s easy to forget that, in spite of periodic frustrations and disappointments, very real progress has been and continues to be made in the war against cancer. Decades of research have given us a much better understanding of how cancer operates at the cellular level. Developments in cancer prevention, screening, and therapy have saved millions of lives. Although there are still 1.5 million new cases of cancer diagnosed in the U.S. every year, the country now also has at least 11 million survivors of various types of cancer. But it’s important to remember that virtually all types of cancer are either aggressive at the onset, or eventually become aggressive.

    In the case of breast cancer, there are now 2.5 million Americans who are living with the disease, with 230,000 new cases detected annually. There are two genes which have been associated with aggressive breast cancer: Her2 and Top2. Even though Herceptin, a $1.8 billion drug marketed by Roche, is an effective treatment for Her2, there are currently no approved therapies that target Top2. The Top2 gene encodes Topoisomerase II, an enzyme that unwinds DNA and is required for cell proliferation. Overexpression of Topoisomerase II allows the cell to divide more rapidly and as a result become more aggressive. It has been associated with breast, prostate, colon, lung, and other deadly cancers. Inhibition of Top2 activity is critical to treat multi-drug resistant breast cancer and other types of aggressive cancer, such as small-cell lung cancer.

    Adva-27a, lead compound of Sunshine Biopharma, if approved, will be the only Topoisomerase II inhibitor on the market. Shown to be 16 times more effective at killing multi-drug resistant breast cancer cells than Etoposide, the most commonly used drug, Adva-27a can be used to treat other Top2 positive cancer types, such as lung, prostate, colon, stomach, and ovarian cancer. As the only Top2 inhibitor, and since it could help terminally ill patients, Adva-27a is likely to be granted fast-track designation.

    For additional information, visit the company’s websites at SunshineBiopharma.com

    Please see disclaimer on the QualityStocks website: disclaimer.qualitystocks.net
    Stocks: SBFM
Back To QualityStocks' Instablog HomePage »

Instablogs are blogs which are instantly set up and networked within the Seeking Alpha community. Instablog posts are not selected, edited or screened by Seeking Alpha editors, in contrast to contributors' articles.

Comments (1)
Track new comments
  • mrwrnc
    , contributor
    Comments (24) | Send Message
     
    Preclinical studies are basically completed...believe we'll see P1 beginning by Q4 or soon thereafter. Their drug could be one of the major breakthroughs in cancer treatment...and right now the stock is dirt cheap. Problem here looks to be the B/S...no cash at the moment....so one has to assume we'll see dilution. CEO/Advamonics owns 70% of the stock....float is only 8.5MM....

     

    SBFM Share Structure Verified With CFO Camille Sebaaly via Post #1020 On 12/27/11

     

    Authorized --- 200 M
    Outstanding ~ 48.4 M
    Float ~ 8.5 M

     

    Insiders Owned & Restricted ~ 39.9 M
    26 Apr 2012, 11:14 AM Reply Like
Full index of posts »
Latest Followers

StockTalks

More »
Posts by Themes
Instablogs are Seeking Alpha's free blogging platform customized for finance, with instant set up and exposure to millions of readers interested in the financial markets. Publish your own instablog in minutes.